Riskpilot← Back to searchSign inGet full accessTT 1919 ApS
APSActiveCVR 24239470Egelund 5Business and other management consultancy activities · NACE 7020Est. 1999— employees
Revenue 2025
DKK 104K
-57% vs 2024
EBITDA margin
63.5%
+11% vs 2024
Equity ratio
90.3%
Financial strength
Net profit 2025
DKK -3,6M
-100% vs 2024
| Revenue | DKK 104K | -57% |
| EBITDA | DKK 66K | +11% |
| Net profit | DKK -3,6M | -100% |
| Total assets | DKK 20,9M | -24% |
| Equity | DKK 18,8M | -17% |
| Employees | — | — |
Legal name
TT 1919 ApS
CVR number
24239470
Legal form
Anpartsselskab
NACE code
7020 · Business and other management consultancy activities
Founded
1. august 1999
Share capital
DKK 621.000
Employees
—
VAT registered
Yes
Audit selected
No
Last report
2025-04-30
Financial year
January – December
Signatory rights
Selskabet tegnes af enten direktøren og formanden for
bestyrelsen, direktøren sammen med 2 bestyrelsesmedlemmer eller af formanden
sammen med 1 bestyrelsesmedlem.
Company purpose
Virksomhedens formål er investeringsvirksomhed i andre selskaber (hel- eller delejede), ejendomme, værdipapirer og andre investeringsgoder, produktion, handel og konsulentvirksomhed i såvel indland og udland samt undervisning og forskning.
Address
Egelund 5
Phone
+4561677277
Email
post@vokan.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 553 | 650 | 262 | 755 | 349 | 653 | 459 | 104 | -6 | 319 | 765 | 370 | 239 | 104 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | 360 | 531 | 120 | 617 | 231 | 468 | 298 | -84 | -112 | 197 | 594 | 244 | 59 | 66 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | 360 | 531 | 120 | 617 | 231 | 468 | 298 | -84 | -112 | 197 | 594 | 244 | 59 | 66 |
| Net financials | -1.055 | 1.090 | 8.172 | 196 | -1.306 | 2.750 | 402 | 4.290 | -992 | 1.854 | 215 | 6.891 | -1.861 | -3.662 |
| Profit before tax | -695 | 1.621 | 8.292 | 813 | -1.076 | 3.218 | 701 | 4.205 | -1.104 | 2.051 | 809 | 7.136 | -1.801 | -3.596 |
| Tax | -107 | -370 | 209 | -696 | -298 | -202 | 120 | -0 | -118 | 236 | 121 | 15 | -0 | -0 |
| Net profit | -588 | 1.991 | 1.524 | 1.509 | -778 | 3.419 | 581 | 4.205 | -986 | 1.815 | 688 | 7.120 | -1.801 | -3.595 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 22.185 | 19.470 | 28.285 | 20.051 | 20.384 | 28.701 | 28.630 | 24.278 | 20.312 | 25.507 | 23.550 | 30.090 | 27.396 | 20.853 |
| Equity | 12.196 | 9.782 | 11.307 | 12.816 | 11.938 | 15.358 | 15.939 | 16.532 | 15.438 | 19.451 | 20.026 | 24.824 | 22.728 | 18.828 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.037 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 9.990 | 9.688 | 16.978 | 7.235 | 8.446 | 13.343 | 12.691 | 7.746 | 3.837 | 6.057 | 3.524 | 5.266 | 4.667 | 2.025 |
| Total debt | 9.990 | 9.688 | 16.978 | 7.235 | 8.446 | 13.343 | 12.691 | 7.746 | 4.873 | 6.057 | 3.524 | 5.266 | 4.667 | 2.025 |
EBITDA margin
63.5%
This company
15.8%
Market median
+302% vs market
20122025
Equity ratio
90.3%
This company
38.2%
Market median
+136% vs market
20122025
Return on equity
-19.1%
This company
18.4%
Market median
-204% vs market
20122025
Net profit margin
-3463.2%
This company
8.1%
Market median
-42856% vs market
20122025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20122025
Debt / equity
0.11×
This company
0.62×
Market median
+82% vs market
20122025
- Annual report 2025Filed via CVR / Virk · Period 2024-05-01 – 2025-04-30
- Annual report 2024Filed via CVR / Virk · Period 2023-05-01 – 2024-04-30
- Annual report 2023Filed via CVR / Virk · Period 2022-05-01 – 2023-04-30
- Annual report 2022Filed via CVR / Virk · Period 2021-05-01 – 2022-04-30
- Annual report 2021Filed via CVR / Virk · Period 2020-05-01 – 2021-04-30
- Annual report 2020Filed via CVR / Virk · Period 2019-05-01 – 2020-04-30
- Annual report 2019Filed via CVR / Virk · Period 2018-05-01 – 2019-04-30
- Annual report 2018Filed via CVR / Virk · Period 2017-05-01 – 2018-04-30
- Annual report 2017Filed via CVR / Virk · Period 2016-05-01 – 2017-04-30
- Annual report 2016Filed via CVR / Virk · Period 2015-05-01 – 2016-04-30
- Annual report 2015Filed via CVR / Virk · Period 2014-05-01 – 2015-04-30
- Annual report 2014Filed via CVR / Virk · Period 2013-05-01 – 2014-04-30
- Annual report 2013Filed via CVR / Virk · Period 2012-05-01 – 2013-04-30
- Annual report 2012Filed via CVR / Virk · Period 2011-05-01 – 2012-04-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Founder | 1999 | — | — | |
| Founder | 1999 | — | — | |
HS Audit | Audit | 1999 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2021 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 33.3% | 33.3% | 2023 | |
| Individual | 25.0% | 25.0% | 2023 | |
IGLO 1218 ApS | Company | 15.0% | 15.0% | 2023 |
| Individual | 0.0% | 5.0% | 2021 | |
| Individual | 0.0% | 5.0% | 2021 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
TT 1919 ApS 
Nordic Pharma Lab ApSBoard members of TT 1919 ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anna-Signe Lindasdatter Troelsen Holst | Founder | 0 companies |
| Sarah Elisabeth Lindasdatter Troelsen Krarup | Founder | 0 companies |
| Henrik Søeborg | Audit | 0 companies |
| Morten Kruse Hendriksen | Board of Directors | 0 companies |
| Mads Trier Munk | Board of Directors | 0 companies |